I’ll be attending the annual World Conference on Lung Cancer (#WCLC2018) in Toronto Canada later this month. For those who are interested, I will be making two presentations. Hope I’ll see you in the audience!
OA10 – Right Patient, Right Target & Right Drug – Novel Treatments and Research Partnerships
Tuesday 9/25 10:00 AM to 12:00 PM
Oral Abstract Session in the Targeted Therapy Track
Moderated by Howard (Jack) West, Jyoti Patel
ES05 – Collaboration Between Stakeholders to Improve Lung Cancer Research
Tuesday 9/25 15:15 PM to 16:45 PM
Education Session in Advocacy Track
Moderated by Bonnie Addario, Toshiyuki Sawa
Are you from Oregon? You may be losing a very important tool to help you survive cancer. Please stand up to keep providing Medicaid coverage of FDA approved comprehensive genomic sequencing. Many lives depend on it!
OREGON CALL TO ACTION!
The state of Oregon Health Authority Health Evidence Review Commission (HERC) recently released proposed guidance to not provide coverage for the use of FDA-Approved Next Generation Sequencing (NGS) tests for cancer patients in the state with Medicaid.
LUNGevity Foundation and Caring Ambassadors are seeking volunteers–both lung cancer survivors and health care professionals–who live in the state of Oregon, to provide testimony at a public meeting on this issue scheduled for 1:00pm-4:00pm on September 27, 2018 in Wilsonville, Oregon. Ideal testimony would be provided by survivors who have received NGS, or other comprehensive biomarker testing, to guide their treatment and by health care professionals who order, consult, or care for patients who have received NGS, or other comprehensive biomarker testing.For more information or to volunteer, please contact:
A copy of the comments submitted by LUNGevity Foundation to the HERC can be found here.
Thanks to Matt Ellefson at SURVIVEiT! for helping to make this need known.
Image credit: Microsoft
The journal Trends in Neurosciences published an article June 12, 2018 calling for more research into cognitive impairment caused by cancer treatment. Unfortunately, it’s behind a paywall. To get an overview of the content, read Cancer Today’s July 18, 2018 article “What is ‘Chemobrain’?” , which is an interview the article’s lead author, Todd Horowitz of the National Cancer Institute.